CSI Market
Sign In | Register

Immunogen inc (IMGN) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access IMGN Annual Cash Flow →
Changes in quarterly cash flow trends offer perspective on how Immunogen inc funds operations, investments, and shareholder returns.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2023)
9 Months 		(Jun 30 2023) (Mar 31 2023) (Dec 31 2022) (Sep 30 2022)
Operating Activities
Income-14.51
Depreciation & amortization1.30
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-17.57
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation22.37
Income (Loss) from Equity Method Investments0.00
Increase (Decrease) in Restricted Cash for Operating Activities0.00
Amortization Deferred Lease Incentive-
Marketable Securities Gain Loss-
Non Cash Royalty Revenue Related To Sale Of Future Royalties-8.49
Non Cash Interest Expense From Sale Of Future Royalties2.69
Increase Decrease In Customer Asset-1.50
Increase Decrease In Contract With Customer Asset-
Operating Lease Right Of Use Asset Amortization-
Increase Decrease In Contract With Customer Liability13.69
Operating Lease Impairment Loss-
Right Of Use Asset Obtained In Exchange For Operating Lease Liability1.89
Income taxes0.00
Gain (Loss) on Sale of Derivatives0.00
Accounts Receivable-114.05
Increase (Decrease) in Accounts Payable-20.40
Increase (Decrease) in Other Accrued Liabilities7.47
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-7.71
Other Working Capital-0.15
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-2.73
Discontinued operations0.00
Net Cash flow from Operating Activities-137.69
Investing Activities
Capital Expenditures-1.64
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Payments for (Proceeds from) Derivative Instrument, Investing Activities0.00
Payments For Costs Related To Sale Of Future Royalties-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-1.64
Financing Activities
Short-term debt Net71.82
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock397.91
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities469.73
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-139.33
Total Cash Flow330.40
4 historic quarters locked

Sign in to unlock the full Immunogen inc cash flow history.

Sign In Create Free Account

About Immunogen Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001558370-23-017411

Figures are derived from filed reports and may be restated. Historical data is subject to revision.